Video

Zip Codes and Health Equity

The US is composed of tens of thousands of zip codes, and demographics and income levels can change dramatically within a five-mile radius. How are pharma companies addressing this reality?

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Gen Li
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Related Content
Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment
August 3rd 2025

Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma
August 3rd 2025

Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma

Don Tracy, Associate Editor
Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib combination to address unmet needs in second-line treatment for endometrial carcinoma patients.
Collaborating for Smarter AI Solutions in Oncology at Johnson and Johnson
August 3rd 2025

Collaborating for Smarter AI Solutions in Oncology at Johnson and Johnson

Don Tracy, Associate Editor
Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of collaboration across the healthcare community to develop inclusive and effective AI solutions that enhance decision-making and patient outcomes in oncology.
AbbVie Positions Temab-A ADC for Tumor-Agnostic Use in Multiple Cancers
August 3rd 2025

AbbVie Positions Temab-A ADC for Tumor-Agnostic Use in Multiple Cancers

Don Tracy, Associate Editor
Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company is advancing Temab-A across multiple tumor types targeting c-Met, with the goal of establishing it as a pipeline-in-a-molecule.
What Drives AbbVie’s Solid Tumor Strategy Following ASCO 2025 Insights
August 3rd 2025

What Drives AbbVie’s Solid Tumor Strategy Following ASCO 2025 Insights

Don Tracy, Associate Editor
Pedro Valencia, VP, asset strategy leadership, oncology, outlines how unmet need, treatment stagnation, and pipeline innovation shape the company’s approach to solid tumor oncology following key data presented at ASCO 2025.
Nicola Partridge
August 3rd 2025

The Opportunity for Digital to Advance Women’s Health: Q&A with Nicola Partridge

Mike Hollan
Research has shown a gap between the female patient experience compared to those of men.